Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clotrimazole vaginal tablet in vulvovaginal candidiasis (VVC)
CTR20241402Phase 3Completed
- Sponsor
- Beijing Fuyuan Pharmaceutical
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clotrimazole in vulvovaginal candidiasis (VVC) (3 arms), sponsored by Beijing Fuyuan Pharmaceutical. Primary endpoint: Combined clinical and mycological cure rate. Started Apr 2024; status: completed.
02
Drugs
clotrimazole
03
Conditions
vulvovaginal candidiasis (VVC)
Beyond the preview
Go deeper on CTR20241402.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241402.